Parallel Advisors’s LeMaitre Vascular LMAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.42K Hold
13
﹤0.01% 3468
2025
Q4
$1.05K Hold
13
﹤0.01% 3284
2025
Q3
$1.14K Hold
13
﹤0.01% 3190
2025
Q2
$1.08K Buy
13
+5
+63% +$418 ﹤0.01% 3182
2025
Q1
$671 Sell
8
-24
-75% -$2.23K ﹤0.01% 3191
2024
Q4
$2.95K Buy
32
+24
+300% +$2.31K ﹤0.01% 2833
2024
Q3
$743 Hold
8
﹤0.01% 3098
2024
Q2
$658 Sell
8
-120
-94% -$8.82K ﹤0.01% 3041
2024
Q1
$8.49K Buy
128
+120
+1,500% +$7.41K ﹤0.01% 2374
2023
Q4
$454 Sell
8
-128
-94% -$6.71K ﹤0.01% 3072
2023
Q3
$7.41K Buy
136
+128
+1,600% +$7.59K ﹤0.01% 2340
2023
Q2
$538 Hold
8
﹤0.01% 3082
2023
Q1
$412 Hold
8
﹤0.01% 3162
2022
Q4
$368 Hold
8
﹤0.01% 3093
2022
Q3
$0 Sell
8
-81
-91% -$4.05K ﹤0.01% 3349
2022
Q2
$4K Buy
+89
New +$3.98K ﹤0.01% 2356
2021
Q3
Sell
-21
Closed -$1K 3181
2021
Q2
$1K Buy
+21
New +$1.12K ﹤0.01% 2761
2020
Q2
Sell
-8
Closed 2593
2020
Q1
$0 Hold
8
﹤0.01% 2534
2019
Q4
$0 Buy
+8
New +$276 ﹤0.01% 2455

Other funds holding LMAT

Parallel Advisors's LMAT Position: Q1 2026 in Review

Parallel Advisors held its LeMaitre Vascular (LMAT) position steady in Q1 2026 at 13 shares worth $1.42K. The position accounts for ﹤0.01% of the portfolio, ranked #3468.

Parallel Advisors first reported a position in LMAT in Q4 2019 and has held it in 19 quarters since. The position peaked at $8.49K in Q1 2024. 339 funds tracked by Wall St. Rank hold LMAT as of Q1 2026.

  • Parallel Advisors held 13 shares of LeMaitre Vascular worth $1.42K as of Q1 2026.
  • Parallel Advisors left its LeMaitre Vascular share count unchanged in Q1 2026.
  • LeMaitre Vascular made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3468 holding.
  • Parallel Advisors first reported a position in LeMaitre Vascular in Q4 2019 and has held it in 19 quarters since.
  • Parallel Advisors's LeMaitre Vascular position peaked at $8.49K in Q1 2024.
  • 339 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.